Both are GHRH analogs—one is a medicine
Tesamorelin and CJC-1295 are both analogs of growth-hormone-releasing hormone (GHRH): they act on the GHRH receptor in the pituitary to promote growth-hormone release. The most important difference is regulatory. Tesamorelin is an approved medicine (authorized in some jurisdictions for HIV-associated lipodystrophy), whereas CJC-1295 is a research compound that is not an approved drug for general human use. This guide compares their science, not their use.
Molecular design and stabilization
Native GHRH is degraded rapidly in plasma. Both peptides are engineered for stability: tesamorelin is a stabilized GHRH(1-44) analog, while CJC-1295 is a modified GHRH(1-29) fragment. CJC-1295 exists in two research forms—with and without a Drug Affinity Complex (DAC). The DAC version binds albumin to greatly extend circulating half-life; the 'no-DAC' version (sometimes called modified GRF 1-29) is much shorter acting.
Half-life is the practical dividing line
CJC-1295 with DAC is notable in the literature for a substantially extended half-life measured in days, producing a sustained 'bleed' of GH-axis stimulation. Tesamorelin and no-DAC CJC-1295 are shorter acting, producing more pulsatile stimulation. This half-life contrast is the property researchers most often use to distinguish the DAC and no-DAC approaches.
Evidence base and endpoints
Because tesamorelin is an approved drug, it has controlled clinical trial data behind a specific indication and defined manufacturing standards. CJC-1295 is studied in a research context and lacks that clinical authorization and oversight. When comparing 'evidence,' this asymmetry matters: an approved medicine and a research peptide sit in fundamentally different categories of scrutiny.
How they pair with ghrelin secretagogues
GHRH analogs are frequently studied alongside ghrelin-receptor secretagogues like ipamorelin, because the two pathways act on different receptors and are complementary at the pituitary. That is why 'CJC-1295 + ipamorelin' appears so often as a research pairing—covered in our dedicated CJC-1295 vs ipamorelin guide.
Regulatory and safety framing
Tesamorelin's authorization applies to a specific approved indication under medical supervision—not general enhancement. CJC-1295 is not an approved drug for general human use in Canada. Nothing here is dosing guidance or an endorsement; consult qualified professionals and Health Canada resources for anything beyond educational study.
FAQ
Is tesamorelin the same as CJC-1295?+
No. Both are GHRH analogs acting on the GHRH receptor, but tesamorelin is an approved medicine (for HIV-associated lipodystrophy in some jurisdictions) with clinical trial data, while CJC-1295 is a research compound that is not approved for general human use.
What is the difference between CJC-1295 with and without DAC?+
The Drug Affinity Complex (DAC) binds albumin to extend circulating half-life to days, giving sustained GH-axis stimulation. The no-DAC form (modified GRF 1-29) is much shorter acting and more pulsatile.
Which has stronger evidence behind it?+
Tesamorelin, by regulatory category: as an approved drug it has controlled trials, a labeled indication, and defined manufacturing standards. CJC-1295 is studied in research settings without that clinical authorization.
Why are GHRH analogs paired with ipamorelin in research?+
Because GHRH analogs and ghrelin-receptor secretagogues act on different receptors and are complementary at the pituitary, so they are often studied together. See our CJC-1295 vs ipamorelin guide for more.